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Background: Estrogen receptors alpha (ER) are implicated in many types of female cancers, and are the common
target for anti-cancer therapy using selective estrogen receptor modulators (SERMs, such as tamoxifen). However,
cell-type specific and patient-to-patient variability in response to SERMs (from suppression to stimulation of cancer
growth), as well as frequent emergence of drug resistance, represents a serious problem. The molecular processes
behind mixed effects of SERMs remain poorly understood, and this strongly motivates application of systems
approaches. In this work, we aimed to establish a mathematical model of ER-dependent gene expression to explore
potential mechanisms underlying the variable actions of SERMs.
Results: We developed an equilibrium model of ER binding with 17β-estradiol, tamoxifen and DNA, and linked it to
a simple ODE model of ER-induced gene expression. The model was parameterised on the broad range of literature
available experimental data, and provided a plausible mechanistic explanation for the dual agonism/antagonism
action of tamoxifen in the reference cell line used for model calibration. To extend our conclusions to other cell
types we ran global sensitivity analysis and explored model behaviour in the wide range of biologically plausible
parameter values, including those found in cancer cells. Our findings suggest that transcriptional response to
tamoxifen is controlled in a complex non-linear way by several key parameters, including ER expression level,
hormone concentration, amount of ER-responsive genes and the capacity of ER-tamoxifen complexes to stimulate
transcription (e.g. by recruiting co-regulators of transcription). The model revealed non-monotonic dependence of
ER-induced transcriptional response on the expression level of ER, that was confirmed experimentally in four
variants of the MCF-7 breast cancer cell line.
Conclusions: We established a minimal mechanistic model of ER-dependent gene expression, that predicts complex
non-linear effects in transcriptional response to tamoxifen in the broad range of biologically plausible parameter values.
Our findings suggest that the outcome of a SERM’s action is defined by several key components of cellular micro-
environment, that may contribute to cell-type-specific effects of SERMs and justify the need for the development of
combinatorial biomarkers for more accurate prediction of the efficacy of SERMs in specific cell types.
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Estrogen receptor mediated signalling is highly implicated
in the growth regulation of hormone dependent cancers,
such as breast, ovarian and uterine cancer [1,2].
According to the current concept, estrogen receptor
alpha (ER) belongs to the class of nuclear hormone recep-
tors that act as transcription factors, controlling expression
of genes that regulate cell survival and proliferation. The
molecular mechanisms of ER-induced transcriptional ac-
tivation include binding of ER with its natural ligand
17β-estradiol, upon which the receptor undergoes a con-
formational change, which favors its dimerisation and
binding to the specific promoter sequences within DNA -
so called Estrogen Response Elements (ERE). Binding of an
ER-ligand complex to ERE initiates a further cascade of
processes, resulting in the assembly on the promoter of a
multi-component ER-transcription complex. This involves
combinatorial binding of multiple co-regulator proteins,
which can either activate or suppress transcription of ER-
responsive gene [3,4]. The composition of the transcription
complex is believed to be cell and tissue-specific [5-7].
Current therapeutic strategies in the treatment of ER-
positive cancers include administration of drugs that act
as estradiol competitors, displacing hormone in its bind-
ing site on ER (e.g., tamoxifen, raloxifene). These drugs
were initially designed as anti-estrogens with a view to
suppress pro-mitogenic actions of estradiol in cancer
cells [8,9]. However, as revealed by further studies, the
developed compounds were capable of exhibiting both
antagonist and agonist activities, depending on the type
of tissue, in which they acted, that led to redefinition of
these drugs as Selective Estrogen Receptor Modulators
(SERMs) [10-12]. In particular, tamoxifen can act as an
ER antagonist in breast cancer cells [13], but, at the
same time it has a partial agonistic effect in the endo-
metrium, resulting in endometrial hyperplasia and an
increased risk of cancer [5,10].
Multiple studies have been undertaken to tackle the
molecular mechanisms, underlying the dual agonist/an-
tagonist action of SERMs and the associated emergence
of drug resistance. Significant efforts have focused on
deciphering the role of transcriptional co-regulators
[14,15]. Other studies have attempted to define specific
gene expression signatures, associated with sensitivity or
resistance to SERMs [16-18]. Recent study of Ross-Innes
et al. [19] highlighted the importance of genome-wide
ER-binding events, and presented convincing evidence
that specific FOX-1 mediated "reprogramming" of ER
binding with DNA in breast tumors significantly contri-
butes to the variation in clinical outcome.
Despite significant progress in understanding the system
of ER-related signalling, and advances in deciphering the
molecular components involved in cellular response to
estrogens and SERMs, the mechanisms responsible for celltype specific and patient-to-patient variability in respon-
ding to SERMs still remain not fully understood.
The high level of combinatorial complexity of early tran-
scriptional events, initiated by ER binding with ERE, as
well as an intricate web of signalling pathways associated
with ER (e.g., growth factor and cytokine-related signal-
ling), makes it impractical to analyse the ER signalling net-
work based solely on intuitive reasoning. This strongly
motivates the application of mathematical abstraction and
computational approaches. However, before now, sur-
prisingly little has been done to address the complexity of
ER-related signalling with modelling approaches, and
mathematical models of estrogen related processes are still
sparse. In 1993 Dove and Schonenberger [20] presented a
simple equilibrium model of ER binding with estrogen
and DNA that was successfully applied to explain different
types of experimentally registered estrogen dose–response
curves. Recently Tyson et al. highlighted the importance
of developing a comprehensive mathematical model of the
estrogen signalling network in breast epithelial cells, and
outlined the roadmap for the development of such a
model [1].
In this study we aimed to develop a simple mechanis-
tic model for estrogen-induced gene expression, focusing
on the very first steps of cellular response to estrogens
and SERMs, mediated by ER binding with DNA. We
established a detailed equilibrium model of ER binding
with two types of ligands (natural hormone and a SERM)
and DNA ERE, and linked it to a simplified ODE model of
transcription and translation of an estrogen-responsive
gene. We parameterised the model on the broad range of
literature available experimental data, including in vitro
data on ER binding with ligands and DNA, and the re-
porter gene expression data, obtained in HEK 293/hERα
cell line, treated with 17β-estradiol and tamoxifen.
We demonstrate that the analysis of the steady state
solution of the developed model provides a plausible
mechanistic explanation for the dual agonist/antagonist
action of tamoxifen in the HEK 293/ERα cell line used
for model calibration. We further explore the applicabi-
lity of our conclusions to a more general context (i.e. to
other cell types) by running global sensitivity analysis
and exploring the behaviour of the model solution in the
wide range of biologically plausible parameter values.
We demonstrate that the magnitude of ER-dependent
transcriptional response to tamoxifen is controlled in a
complex non-linear way by several key parameters, in-
cluding expression level of ER, background concentra-
tion of 17β-estradiol, amount of estrogen-responsive
elements and the capacity of ER-tamoxifen complexes
to induce transcription (e.g. via recruiting specific
co-regulators of transcription). We discuss the potential
applicability of these findings in the context of bio-
marker research.
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Mathematical model
Our model of estrogen-induced gene expression consists
of three main blocks, corresponding to three key types
of processes included in the system: (1) interaction of ER
with ligands; (2) binding of receptor-ligand complexes
with DNA ERE and (3) ER-induced transcription and
translation.
The general scheme of the model is presented in Figure 1.
Figure 1A describes the processes of ER dimerisation and
binding with ligands, and was constructed based on the fol-
lowing reasoning. As suggested by structural studies [21]
both ligand binding and dimerisation activities of the ER
monomer are located within its ligand-binding domain
(LBD), with ligand binding cavity and ER dimerisation sur-
face spatially separated from each other. Therefore, in terms
of our model we considered them as two distinct binding
sites within ER - one for ligand binding, and one for bind-
ing with other monomers. Under these assumptions we
considered the possibility of formation of nine different
receptor-ligand complexes, resulting from interaction be-
tween ER monomers and two different receptor ligands - a
natural agonist hormone 17β-estradiol (H), and a SERM,
which acts as a competitive inhibitor (I), occupying ER hor-
mone binding site. The lower part of the scheme shown in
Figure 1A depicts various receptor-ligand complexes and
their transformations, resulting from ER dimerisation and
interaction with the hormone (reactions 1–6), while theFigure 1 General scheme of the processes included in the
model of ER-dependent gene expression. (A) Reactions of ER
dimerisation and binding with two types of ligands - natural
hormone (H) and an inhibitor (I); (B) Binding of dimeric forms of
receptor-ligand complexes with ERE; (C) Synthesis and degradation
of mRNA (r) and protein (p). The detailed description of the scheme
is given in the text.upper part describes competitive binding of an anti-
estrogenic drug (I) to ER (reactions 7–9) and dimerisation
of the ER-inhibitor complexes (reactions 10 and 11).
In our model we consider a possibility of heterodimer
formation (ER2HI), with one ER monomer bound to
the hormone, and another one - to an inhibitor (reactions
12–14).
We assume that binding of a hormone or an inhibitor
by an ER monomer can affect ER dimerisation, that may
result in differences in kinetic constants assigned to
stages 1, 5, 6, 10, 11 and 12. We also assume that mono-
meric (ER) and dimeric (ER2) forms of the receptor dif-
fer by their affinity to ligands.
It must be noted, that experimental confirmation of the
existence of each of the receptor-ligand binding combina-
tions included in the model poses significant challenges,
because of practical difficulties associated with discriminat-
ing between the experimentally registered effects of similar
binding complexes (e.g., ER2H and ER2H2). However, the
existence of free (unliganded) ER dimer (ER2), and its cap-
acity to stimulate ER-dependent transcription have been
confirmed in a number of experimental studies [22-25].
For example, Tamrazi et al. [23] confirmed the possibili-
ty of ER2 formation and demonstrated that addition of
ligands affected dimer stability in dose-responsive manner,
with maximal effect observed when receptor is fully satu-
rated with ligand. This provides an indirect evidence for
existence of ER2H and ER2I complexes. Indeed, if both
ER2H2 and ER2 do exist, than ER2H has to be included
into consideration based on the step-wise mechanism of
binding/dissociation of two hormone molecules to/from
ER2H2. Similar reasoning can be used to justify existence
of ER2I complexes. The existence of ER2HI complex can
be questionable, but we included it in the model since its
occurrence is theoretically possible.
Figure 1B describes binding of different forms of ER2
dimers to ERE sequences of DNA (D) (reactions
15–20). Here we assume that various dimeric forms of
ER-ligand complexes have different affinities for ERE (i.e.
the values of Kd for reactions 15–20 differ from each
other). In our model we do not consider binding of the ER
monomers with ERE, since this process was shown to be
much less efficient than binding of ER dimers [26-28]. In
particular, Carlsson et al. (1995) [27] reported 20-fold
lower association rate constant of the hormone-receptor
complex to ERE at low concentrations of ER, when the pre-
dominant form of ER is a monomer, as compared to higher
concentrations (ER > 12 nM), when the majority of ER
present as homodimers. Metzger et al. (1995) also reported
that the wild type ER binds in vitro to ERE as a dimer, irre-
spective of the presence or absence of estrogen [28].
Finally, reactions 21 and 23 shown in Figure 1C depict
the processes of transcription (synthesis of mRNA, r) and
translation (synthesis of the protein, p), whereas reactions
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respectively. In our model we assume that the rate of
mRNA synthesis is proportional to the level of active ER-
ERE transcription complexes.
The full ODE system describing the dynamics of the
system shown in Figure 1 would include 16 ODEs, four
algebraic equations and 45 independent parameters (see
Additional File 1). The reliable identification of all kinetic
parameters of such ODE system would represent a
challenging task due to the lack of available dynamic data.
Importantly, the majority of existing experimental studies
into estrogen-induced transcription and effects of SERMs
focus on exploring various kinds of dose–response rela-
tionships, quantifying the response of the experimental
system to specific ER ligands, in the broad range of ligand
concentration. The typical experimental setup includes
several hours pre-incubation of either purified estrogen
receptors, or ER expressing cells with relevant receptor
ligands (hormones, SERMs), followed by the measurement
of specific receptor-ligand binding or by quantification of
cellular response to the treatment (e.g. expression of
specific proteins). Such a significant time of pre-incubation
with the ligands (from a few hours in vitro up to 72 h
in vivo and cell-based systems) allows assuming that the ex-
perimental system reaches either an equilibrium (in vitro)
or a steady state (in vivo).
Thus, to be able to utilize the available data on equilib-
rium binding and dose–response curves for model par-
ameterisation, we needed to consider the model at an
equilibrium or a steady state.
It is worth noting, that equilibrium approximation of ER
binding with ligands and DNA ERE may in fact be suffi-
cient for a simplified description of ER dependent gene
expression, since the system allows separation of the time
scales between faster ligand binding processes and slower
gene expression events. Thus we established an equili-
brium model of ER binding with two competing ligands
and DNA. A similar equilibrium approach was previously
applied by Dove et al. [20] to describe ER binding with a
single ER agonist and DNA, that allowed successful rep-
roduction and explanation of different patterns of dose
response curves measured in vivo. Our developed equilib-
rium model was then linked to a simplified kinetic model
of transcription and translation of an ER-dependent gene,
and the steady state solution of the whole model has been
analysed. Further details of model development are given
in Methods.
Model parameterisation
The values of model parameters have been estimated
based on experimental data available from the litera-
ture. It is worth noting, that although there exist many
available estimates for some of the kinetic constants of
ER interaction with ligands, there is a high level ofdiversity in the available data - e.g., the parameter
values are often reported for various forms of the
receptor (ERα, ERβ), extracted from different organ-
isms (mice, calf, rat, human), and measured under a
variety of experimental conditions (e.g. at different
temperature). Importantly, most estimates do not
allow discrimination between the ligand binding para-
meters for monomeric and dimeric forms of ER. More-
over, these estimates often have been obtained with the
use of different methods. This results in a significant
discrepancy in the reported values (e.g. for receptor
binding with 17β-estradiol the reported Kd estimates
range from 0.1 [29] to 0.5 [30] and 1 nM [31], depend-
ing on the method and the receptor type used. To re-
duce the level of parametric uncertainty in our model,
we only used those data sets, which were measured for
human ERα (hER). Importantly, where possible, we
have not just re-used the reported values, but re-fitted
the reported experimental curves with our model, to
achieve the best match between theoretical and experi-
mental trajectories. This in most cases resulted in
some level of re-adjustment of the initial parameter
estimates, taken from the literature.
Model parameterisation included three main stages, in
accordance with the model architecture, and following
the strategy of step-by-step integration of multi-level ex-
perimental data within kinetic models [32]. The model
has been decomposed into smaller sub-systems, which
have been parameterised separately with the use of suit-
able experimental data (Figure 2). For example, to iden-
tify parameters of ER interaction with ligands we fitted
the model against published in vitro data on binding of
purified hER with hormone [33] and tamoxifen [34]. To
evaluate Kds for ER interaction with DNA we used the
data on hER binding to ERE DNA [35-37]. The esti-
mated parameters have then been integrated into the
whole system. The parameters of the full system have
been further fine-tuned, via fitting the full model against
the data set, obtained with the use of an in vivo cellular
assay [38].
Further details on calibration of separate blocks of the
model can be found in the Additional File 2. The identi-
fied parameter values are given in Tables 1 and 2.
Despite the broad diversity of experimental data used for
calibration of its separate blocks, the resulting model was
capable of qualitatively matching the tamoxifen dose-
dependence patterns of ER-induced gene expression in a
reporter cell line, and allowed realistic description of a
number of important regulatory phenomena, known for
ER-dependent transcription. Moreover, further analysis of
the model provided some valuable insights into potential
mechanisms underlying dual agonism/antagonism action of
tamoxifen in various cell types, as outlined in the next
sections.
Figure 2 Fitting the model of ER-dependent gene expression to multi-level experimental data. (A) The equilibrium model of ER binding
with the hormone was fitted against the data on equilibrium binding of recombinant hERα with labelled estradiol (17β -[6,7 -3H(N)] estradiol),
registered at four different concentrations of hERα: 0.3 (black square); 1.2 (blue triangle); 7 (red circle); and 13 (green diamond) nM. The data were
taken from [33]. ER_b is the concentration of ER binding sites, bound with hormone; Ht -total concentration of labelled estradiol. (B) and (C): The
equilibrium model was used to fit the data on competitive binding of ligands with ER in the presence of labelled 17β-estradiol. The competitive
ligands were: unlabelled 17β-estradiol (B) and tamoxifen (C). The experimental data were taken from [34]. (D) The steady state protein expression
(p) was fitted to the data on reporter gene expression (ALP) in HEK293/hERα cell line treated with tamoxifen (black line) and tamoxifen+0.5 nM
17β-estradiol (blue line); data taken from [38]. Points correspond to experimental data, lines – to theoretical curves. More details on the fitting
procedure and model calibration can be found in the Additional File 2.
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The positive cooperative nature of ER binding with
17β-estradiol has been reported in multiple studies
[29,33,35,39], that revealed a transition from non-coopera-
tive to positive cooperative binding, associated with gradual
increase in ER concentration from low to high levels.
The level of cooperativity is commonly characterised with
the use of Hill coefficient nH, estimated from fitting experi-
mental binding curves with the empirical Hill equation:
B ¼ L½ 
nH
KA½ nH þ L½ nH
where B is a fraction of the receptor binding sites occupied
by ligands, L - concentration of free ligand, KA - ligand con-
centration, causing occupation of half of the binding sites,
and nH - Hill coefficient.
Importantly, our model does not make use of the Hill
equation and nH coefficient to account for the cooperati-
vity of ER binding with ligands. Instead we mechanisticallydescribe the interaction of ER monomers with other ER
monomers and ligands, that allows flexible adjustment of
the model behaviour and its cooperativity level in accor-
dance with ER concentration. It is worth noting, that
reported nH values for hER binding with 17β-estradiol
normally do not exceed 1.4-1.5 [33,35,39]. As can be seen
from Figure 3, our model reproduces a realistic range of
experimentally observed cooperativity, with estimated nH
values ranging from 1.0 to 1.4.
Transcriptional response to tamoxifen in HEK293/hERα
cells has a complex structure
The data on tamoxifen effects in HEK293/hERα cells [38],
used for initial calibration of our model (Figure 2D),
clearly revealed a dual agonist/antagonist activity of the
drug. In particular, in the absence of 17β-estradiol (lower
curve), tamoxifen acted as a partial agonist, stimulating
the ER-dependent expression of the reporter gene (ALP)
in the range of concentrations > 10 nM, that resulted in a
4-fold increase in ALP expression as compared with the
Table 1 Parameters of ER binding with ligands and
DNA ERE
Reaction Kd Value
in the
model,
nM
Existing
experimental
estimates, nM
Reference
ER+ER=ER2 K1 25 >50 [73]
ER2+H=ER2H K2 0.2 0.16 [23]
ER2H+H=ER2H2 K3 0.1 -
ER+H=ERH K4 0.25 0.9 [31]
ERH+ER=ER2H K5
* 20 50 [73]
ERH+ERH=ER2H2 K6
* 8 4 [33]
20 [73]
ER2+I=ER2I K7 10 -
ER2I+I=ER2I2 K8 150 220 [31]
ER+I=ERI K9 30 -
ERI+ER=ER2I K10
* 8.3 < K5 [23]
ERI+ERI=ER2I2 K11
* 41.5 -
ERH+ERI=ER2HI K12
* 26.67 -
ER2I+H=ER2HI K13 0.8 -
ER2H+I=ER2HI K14
* 40 -
ER2+D=ER2D K15 8 40 [35]
2.5 [36]
ER2H+D=ER2HD K16 2.4 -
ER2H2+D=ER2H2D K17 1.2 1.8 ±0.6 [36]
2.0±0.3 [27];
10 [35]
ER2I+D=ER2ID K18 50 -
ER2I2+D=ER2I2D K19 87 14 [37]
ER2HI+D=ER2HID K20 10-20 -
Parameters marked by (*) are dependent on the values of others and have
been calculated as described in Methods.
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tional response caused by 17β-estradiol. Interestingly,
in the presence of 0.5 nM 17β-estradiol, in the tamoxi-
fen concentration range > 100 nM, the drug acted as
as a pure anti-estrogen, causing a suppression of the
reporter gene expression. However in the range of con-
centrations 1–100 nM, tamoxifen was not only inef-
fective in suppressing protein expression, but even had
some stimulatory effect, manifested as a slight increase
in ALP production at 10–50 nM of tamoxifen.
Note, that similar stimulatory effects of tamoxifen on
ER dependent transcriptional activation and cell prolifera-
tion have been reported in other studies [11,40]. For
example, McDonnel et al. [11] reported partial agonism of
tamoxifen in HepG2 cells, transfected with the estrogen-
responsive C3-Luc reporter gene along with an ERα
expression vector. At concentrations 1–100 nM tamoxifen
stimulated expression of the reporter gene, up to 30% ofthe level induced by estradiol. Higher concentrations of
tamoxifen led to suppression of the gene expression. Simi-
lar dose dependences were observed with the use of cell-
proliferation assays, demonstrating that in certain cell
lines and in the concentration range 1–100 nM, tamoxifen
was not just ineffective in suppressing cell proliferation,
but in fact stimulated these processes [41-43].
Since our model was capable of qualitatively matching
the observed effects, we further sought to analyse the
obtained solution to get an insight into potential mo-
lecular mechanisms underlying these phenomena.
In our model the steady state level of ER-dependent pro-
tein expression (p̄) is fully defined by the partial trans-
criptional activation effects caused by various forms of
transcription complexes assembled at ERE, as specified in
equations 22–24 (see Methods). To estimate the contri-
bution of each of these complexes into resulting protein
expression we generated separate trajectories of tamoxifen
dose dependence for each of the terms in the equations
(22–23), in a wide range of tamoxifen concentrations
(Figure 4). According to our analysis, in the absence of es-
tradiol (Figure 4A), and at low tamoxifen (< 10 nM) the
gene expression is maintained at some background level,
provided by free receptor dimers bound with ERE (ER2D).
In the range of 10–100 nM tamoxifen, the ER-dependent
transcription is mainly driven by the ER2ID complexes,
whose contribution gradually increases reaching a peak at
about 50 nM tamoxifen and then steadily drops. At higher
tamoxifen concentrations (>200 nM) the key role in tran-
scription activation shifts to ER2I2D complexes, whose
amount progressively grows with the increase of tamoxifen
concentration. Thus, our analysis suggests that the partial
agonism of tamoxifen in the absence of the hormone
results from transcriptional activation caused by transcrip-
tion complexes formed by ER2 bound with tamoxifen
(ER2ID, ER2I2D).
In the presence of 0.5 nM estradiol (Figure 4B), the
composition of transcriptional response to tamoxifen is
more complex, since it includes stimulatory effects caused
by the hormone-receptor complexes. The model predicts
that at concentration lower than 50 nM, tamoxifen is
unable to effectively antagonise estradiol-induced trans-
cription, because of the high level of transcriptional stimu-
lation, caused by ER2HD complexes (Figure 4B, blue
curve). In the range of 10–100 nM of tamoxifen the input
of ER2HD complexes into overall transcription gradually
decreases, but at the same time there is an additional
"boost" in transcriptional activation, caused by the com-
plexes ER2ID and ER2H2D (Figure 4B, green and magenta
curves). This may explain an agonistic effect of tamoxifen
in the dose range of 10–100 nM, manifested as a charac-
teristic "bump" on the dose response curve for protein ex-
pression (Figure 2D). At higher tamoxifen concentrations
(>100 nM) the stimulatory action of hormone-receptor
Table 2 Parameters of transcription and translation
Process Rate constant Value in the
model, s-1
Existing experimental
estimates, s-1
Reference
mRNA synthesis induced by ER2-hormone complexes ksr 0.195 0.125-0.2 [74]
mRNA synthesis induced by ER2-inhibitor complexes ksr,i 0.02 -
mRNA synthesis induced by ER2-hormone-inhibitor complexes ksr,hi 0.05 -
mRNA synthesis induced by ER2 ksr,b 0.001 -
mRNA degradation kdr
* (0.0025)* 0.001-0.003 [74]
1.5×10-4-0.005 [75]
Protein synthesis ksp
* (0.001)* 3×10-4 - 0.03 [76]
Protein degradation kdp
* (2×10-5)* 1.4×10-5 -3×10-5 [76]
Constant ratio kdpkdrksp κ 5×10
-5
Parameters marked (*) could not be evaluated independently. Use of the dose dependence data only allowed estimation of the ratio κ, as defined in equation
(22). The given values are realistic estimates of kdr, ksp and kdp chosen to satisfy the equation for κ (see Additional File 3 for further details).
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contribution of slower transcribing ER2I2D complexes pro-
gressively increases, until at tamoxifen > 1μM it becomes a
prevailing factor. This is accompanied by a general decrease
in ER-dependent protein expression to about 15% of its ori-
ginal level.
Thus, according to our analysis, in the HEK 293/hERα
cell line, the overall transcriptional response to tamoxi-
fen has a complex structure, defined by partial stimula-
tory effects, caused by various transcription complexes
assembled at ERE. The composition of the response and
contribution of each of the possible transcriptional com-
plexes into overall transcription flexibly changes depen-
ding on the concentration of tamoxifen and background
level of estradiol. Importantly, our analysis suggests that
the observed antagonistic action of high dose tamoxifen
arises from re-distribution of the balance between tran-
scription complexes with lower and higher potency to
stimulate transcription.Figure 3 Cooperativity of ligand binding as observed in the equilibriu
of hormone binding on the total concentration of the hormone, calculated
sites occupied by hormone. (B) Dependence of the apparent Hill coefficien
theoretical curves shown in Figure 3A were presented in traditional Hill co
Hill equation.Global sensitivity analysis of transcriptional response to
tamoxifen
Our findings around the potential mechanism underpin-
ning dual agonism/antagonism action of tamoxifen, pre-
sented above, have been derived from the analysis of a
single model solution, obtained from fitting the model
against the data on tamoxifen effects in a particular cell
line (HEK293/hERα).
In order to extend these conclusions to more general
cases we next sought to explore the model behaviour in a
wider range of plausible parameter values. Indeed, many of
the model parameters (such as background hormone con-
centration, ER expression level, number of ER-dependent
genes, etc.) are likely to be cell-type specific and subject to
biological variation. Moreover, a noticeable biological vari-
ability can be observed even within the same cell line. For
example, Osborne et al. [44] reported considerable bio-
logical differences among MCF-7 breast cancer cells taken
from different laboratories, including variable amounts ofm model of ER binding with hormone. (A) Theoretical dependence
for 1; 5; 10 and 20 nM of ER. Hb – fraction of the receptor binding
t (nH) on ER concentration. To estimate the values of nH, the
ordinates (bound vs unbound ligand) and then fitted with the
Figure 4 Analysis of the composition of transcriptional response to tamoxifen in HEK 293/hERα cell line. The curves represent partial
transcriptional responses caused by various forms of transcription complexes assembled at ERE, calculated as tamoxifen dose dependences of the
following terms: (1) p̅ ER2D = ksr,bER2D/κ; (2) p̅ ER2HD = ksr,hER2HD/κ; (3) p̅ ER2H2D = ksr,hER2H2D/κ; (4) p̅ ER2ID = ksr,iER2ID/κ; (5) p̅ ER2I2D = ksr,iER2I2D/κ; (6)
p̅ ER2HID = ksr,hiER2HID/κ. Concentration of 17β-estradiol was set equal to 0 (A) and 0.5 nM (B) in accordance with the reference experiment [38].
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variation in individual responses to anti-estrogens and
therefore require additional investigation. In addition to
that, little quantitative information is available about
some of the processes, included in the model. For
example, little is known about the interaction of ER
with non- perfectly palindromic ERE, despite the pre-
dominance of non-classical EREs in endogenous genes.
It is also worth noting, that many elementary reactions
considered in the model cannot be studied in isolation,
due to practical difficulties in experimental separation
of the effects of individual reactions from the effects of
others (e.g. it is hardly possible to discriminate
between binding of ER2H and ER2H2 to ERE). These
limitations hamper reliable identification of corre-
sponding model parameters.
Thus, both cell type specific biological variability of pa-
rameter values and the parametric uncertainty associated
with the lack of relevant kinetic data dictated the need to
analyse the model behaviour in a wider parameter space.
To identify the key model parameters, whose variation
may have the biggest impact on the transcriptional re-
sponse to tamoxifen, we used global sensitivity analysis(GSA). The GSA technique allows exploration of the
sensitivity of specific model outputs to simultaneous
variation of multiple model parameters within broad
parameter space, and has recently proven its value for
the analysis of the range of biological systems [45-47].
In the current study we applied GSA technique for the
analysis of the sensitivity of ER-induced transcriptional
response to the variation of all model parameters, at dif-
ferent fixed doses of tamoxifen. As a quantitative mea-
sure of transcriptional activation we used the steady-
state level of protein expression, p̄, as defined in the
equation (22) (see Methods for further details on GSA).
Figure 5 presents the p̄ sensitivity profiles, generated for
three different concentrations of tamoxifen (see Additional
File 3 for full p̄ sensitivity profile in the wide range of ta-
moxifen concentrations).
Independently of the tamoxifen concentration, the
level of p̄ had the highest sensitivity to the total concen-
tration of the estrogen-responsive elements ERE (Dt),
whereas the set of other top-ranked model parameters
changed depending on tamoxifen concentration. In par-
ticular, in the absence and at low tamoxifen (< 0.1 nM)
p̄ was highly sensitive to the parameters ksr,b and ksr,
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by free ER dimers (ER2) and ER dimers bound to the
hormone estradiol (ER2H, ER2H2), respectively. Rela-
tively high sensitivity was also found for the total con-
centration of estradiol (Ht) and the receptor (ERt), as
well as for the affinity of ER2H complexes to DNA ERE
(K16).
At 50 nM tamoxifen, p̄ retained high positive sensitiv-
ity to parameters ksr,b and ksr. At the same time it
became sensitive to the rate of transcription activation
(ksr,i) induced by the receptor-tamoxifen complexes
(ER2I, ER2I2), and acquired negative sensitivity to the
parameter K18, which controls binding of ER2I com-
plexes to ERE. The sensitivity to the total concentration
of ER (ERt) also significantly increased.
At high tamoxifen concentration (1000 nM), the sensiti-
vity profile demonstrated noticeable changes as compared
to lower tamoxifen concentration. In particular, p̄ became
extremely sensitive to the rate of transcriptional activation
induced by tamoxifen-receptor complexes (ksr,i), and to the
total concentration of estrogen receptor (ERt). It also ac-
quired a high negative sensitivity to the parameter of ER2I2
binding to DNA (K19). At the same time the sensitivity to
the parameters controlling transcriptional activation by
free receptor dimers (ksr,b) and receptor-hormone com-
plexes (ksr) became substantially lower. The sensitivity of p̄
to the background hormone concentration also dropped.
Thus, the GSA revealed that out of >20 model para-
meters, only a few had a profound effect on the level of
ER-dependent gene expression, and their ranking order
was dependent on basal tamoxifen concentration. The
parameters with consistently high impact in the wide
range of tamoxifen concentration include: the amount of
ER-dependent promoters (Dt), estrogen receptor level
(ERt), and background hormone concentration (Ht). Im-
portantly, our analysis predicts that at 1000 nM tamoxifen
(that roughly corresponds to tamoxifen concentration
found in tumors) the overall ER-dependent transcriptional
response becomes extremely sensitive to the parameters,
associated with transcriptional activation induced by
tamoxifen-receptor complexes (ksr,i, K19)
Variation of the key control parameters, identified in GSA,
affects transcriptional response to tamoxifen
Next, we embarked on a more detailed investigation of
how the variation of the key control parameters, identified
by GSA, can affect the transcriptional response to tamoxi-
fen. We were particularly interested in analysing these
effects in a realistic concentration range of the biological
components included in our model system. For this pur-
pose, based on literature data, we estimated plausible
ranges of the estrogen receptor levels, DNA ERE, hormone
and drug concentration, observed in human normal and
cancerous breast tissue cells (see Additional File 4 fordetails). In summary, the ER expression level was estimated
to vary from 1pm (sensitivity cut-off for ER negative cells)
to up to 300 nM in ER positive cells, depending on the cell
type (e.g. according to different studies wild type MCF-7
cells contain 10–50 nM ER [48,49]). Typical levels of 17β-
estradiol were found to vary from as low as 30 pM in be-
nign breast cells in postmenopausal women to as high as
1–3 nM in malignant breast tumor cells in premenopausal
women [50]. Tamoxifen levels in blood plasma vary from
10–20 nM at low dose (1 mg/day) up to 200 nM at high
dose tamoxifen (20 mg/day). Importantly in cancer cells
tamoxifen concentrations tend to be significantly higher
than in plasma and range from 100 nM to 2 μM at low
and high dose tamoxifen respectively [51]. The amount of
gene promoters, directly regulated by ER (Dt), was esti-
mated to vary in the range of 0.01-1 nM [19,52,53]
To analyse the steady state transcriptional response to
tamoxifen within identified parameter ranges we gener-
ated a set of 3D graphs, demonstrating how the tamoxi-
fen dose dependence of p̄ changes when each of the key
parameters is varied within its biologically plausible con-
straints (see Figures 6, 7, 8). Further we discuss our most
interesting findings.
The transcriptional response to tamoxifen depends on
the level of ER expression in a non-monotonous way
Model predictions
Figure 6 (A-D) shows the theoretical dependence of
steady state protein expression level p̄ on the total con-
centration of tamoxifen and ER. Simulations were run
for two different background concentrations of estradiol:
higher (0.5 nM, Figure 6A,B) and lower (0.1nM, Figure 6
C,D). These roughly correspond to the upper and lower
limits of 17β-estradiol in breast cancer cells in postme-
nopausal women [50,51].
The model suggests that the level of ER-induced protein
expression is controlled by both tamoxifen and ER concen-
tration in a complex non-linear manner. This is best illu-
strated by the 3D dose dependence graph, generated for
higher estradiol concentration (Figure 6A), which repre-
sents a complex surface with pronounced areas of elevated
protein expression. In a wide range of tamoxifen concen-
trations the dependence of transcriptional response on the
level of ER expression is non-monotonous. In fact, even at
an extremely low concentration of tamoxifen (It ≤1 nM)
there is a notable maximum of transcriptional activation,
observed in the range of 10–50 nM ER. The gradual eleva-
tion of tamoxifen concentration from 1 to 1000 nM results
in a progressive shift of that maximum towards higher
values of ER along with the increase in the amplitude of
the effect, so that the maximal agonism is achieved when
both tamoxifen and ER levels are higher than 100 nM.
The boundaries of the high agonism area can be clearly
seen on the 2D projection of the graph (Figure 6B).
Figure 5 Global sensitivity analysis of transcriptional response to tamoxifen. Global sensitivity profile of the steady state protein expression
p̅ was calculated for (A) 0.1; (B) 50 and (C) 1000 nM tamoxifen. Bars in the diagrams correspond to the PRCC sensitivity indexes calculated for
each of the model parameters, as described in Methods.
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Figure 6 Exploration of transcriptional response to tamoxifen in the wide range of ER concentrations. 3D-graphs (A,C) and their 2D-
projections (B,D), showing the dependence of the steady state protein expression p̅ on the concentration of tamoxifen and estrogen receptor.
Simulations were run for 0.5 (A,B) and 0.1 nM (C,D) of 17β-estradiol. Numbers on the graph 6B correspond to the areas of high and low
tamoxifen agonism, as explained in the text. (E) and (F): Concentration of different forms of receptor-ligand and transcription complexes present
at ERE as a function of ER expression level. The concentration of hormone (Ht) and tamoxifen (It) were fixed at 0.5 and 100 nM respectively.
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scriptional activation can be achieved at significantly dif-
ferent levels of tamoxifen and ER. For instance, elevated
gene expression is seen in the range of 1–50 nM of tam-
oxifen and 10–50 nM ER (area 2 on Figure 6B). However,
a comparable agonistic effect can be also observed at
lower and higher levels of tamoxifen and ER (areas 1 and
3). Another important direct consequence of the non-
linear relationship between transcriptional activation andreceptor level is that the same concentration of tamoxifen
may cause significantly different effects depending on the
background level of ER expression. Indeed, the model pre-
dicts that tamoxifen < 50 nM will have a stimulatory effect
on ER-dependent transcription in cells with ER level lower
than 80 nM, with anticipated maximal agonism for
medium ER expression levels (10–30 nM ER, areas 1 and
2). However the same drug concentration will not cause
any significant transcriptional response if the ER
Figure 7 Testing the effect of the ER expression level on the ER-dependent transcriptional activation. (A) Experimental testing of the
model predictions about the non-monotonous dependence of ER -induced transcriptional activation on the level of ER expression. mRNA
expression levels of TFF1, PGR, MYC and CTSD in four experimental cell lines were measured by real-time RT-PCR using specific primer pairs. RNA
was collected at 48 h and was extracted from either untreated (control) cells or cells treated with 1 nM 17β- estradiol (E2), 1 μM tamoxifen (Tam),
and a combination of 1 nM E2 and 1 μM tamoxifen (E2+Tam). mRNA levels are given in arbitrary units. (B) Relative expression levels of ERα in wild
type MCF-7, LCC1, LCC2 and LCC9 cell lines; (C) Theoretical expression levels of a hypothetical estrogene responsive gene, calculated as p̅ (see
equations 22–24 in Methods) for four different total concentrations of ER: ERt=10; 40; 70 and 100 nM. The parameters of transcriptional regulation
were set equal to those presented in Tables 1 and 2; Hormone (Ht) and tamoxifen (It) concentrations were 1 nM and 100 nM respectively. The
ratio of chosen theoretical ER levels roughly corresponded to the ratio of ER expression levels in four experimental cell lines.
Figure 8 Theoretical dependence of transcriptional response to tamoxifen on. (A) the capacity of tamoxifen-receptor complexes to induce
transcription (ksr,i); (B) the amount of ER-dependent genes (Dt). The concentration of ER and 17β- estradiol were fixed at 50 and 0.5
nM respectively.
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tamoxifen >100 nM will effectively suppress ER-induced
transcription if ER expression is lower than 50 nM (area 5
on Figure 6B), but the same concentration of the drug
may be inefficient and even cause a significant stimulation
of gene expression at higher (>50 nM) levels of ER (area
3). This is in line with experimental findings, indicating
that the development of tamoxifen resistance is often
associated with elevated levels of estrogen receptor [54].
Importantly, as reported in [41], treatment of cancer cells
with high concentration of tamoxifen can in itself stimu-
late ER expression, that potentially provides an additional
basis for agonistic action of tamoxifen.
A similar trend of non-monotonic dependence of tran-
scriptional activation on the amount of ER has also been
predicted for lower levels of estradiol (Figure 6 C and D),
though the effect was much less prominent than found for
higher estradiol concentration. Interestingly, the model
suggests that at a low level of background estradiol, a po-
tentially high transcriptional response can be observed
when both tamoxifen concentration and ER expression
are sufficiently high (the area, highlighted by yellow and
red on Figure 6C and D). In the range of low and medium
tamoxifen concentrations, the magnitude of the transcrip-
tional response is directly dependent on the background
hormone concentration. (See Additional File 5 for an ani-
mation, showing how the characteristic "bump" in the re-
gion of medium ER and tamoxifen levels emerges and
grows with a gradual increase in background estradiol
concentration).
Experimental validation
To test our predictions about the non-monotonous de-
pendence of ER -induced transcriptional activation on
the level of ER expression, we analysed the stimulatory
effects of estradiol and tamoxifen in several cell lines,
which differed by their basal amounts of ER. We investi-
gated four MCF-7 cell lines: wild type MCF-7, MCF-7/
LCC1, MCF-7/LCC2 and MCF-7/LCC9 (Figure 7A). ER
protein levels were significantly elevated in LCC1 and
LCC2, as compared to wild type MCF-7 (from seven- to
eleven-fold) and less markedly in LCC9 (Figure 7B). In
each cell line we measured mRNA expression levels of
four different estrogen-responsive genes, whose activity
is known to be directly regulated by ER: trefoil factor 1
(TFF1), progesterone receptor (PGR), MYC and cathe-
psin D (CTSD). The measurements were run for a var-
iety of conditions, including treatment of the cells with
estradiol, tamoxifen and a combination of both.
Because of potential differences in transcriptional
regulation of TFF1, PGR, MYC and CTSD genes their
expression could not be possibly described with a single
model with the same set of fixed parameters. For ex-
ample, Won Jeong et al. [55] reported significantdifferences in co-regulator recruitment to target promo-
ters of these four genes in breast cancer cells. Account-
ing for these dissimilarities in the model would require
variation of parameters of ER binding with ERE and
corresponding rate constants of transcriptional activa-
tion. Importantly, these parameters are not straightfor-
ward to estimate or measure. For that reason we were
not seeking to directly quantitatively describe the experi-
mental data in Figure 7 with our model. However, to
allow for qualitative comparison of the model and ex-
perimental observations, we calculated the expression
levels of a hypothetical ER-dependent gene for four dif-
ferent levels of ER expression (see Figure 7C).
As expected, there was no exact quantitative match
between modelling results and the experimental data
sets. However, a number of important qualitative trends
observed experimentally were consistent with model
predictions.
Namely, in agreement with the model, in the absence of
any external ER agonists (control) all cells were capable of
maintaining some basal level of gene expression, with the
level of mRNA depending on ER in a non-monotonous
way, noted for all four ER-dependent genes. Addition of
tamoxifen alone resulted in some extra activation of tran-
scription in the majority of genes (TFF1, PGR and CTD),
with the exception of MYC in LCC9 and LCC1, where
transcription dropped slightly, as compared to the control.
Importantly, in line with the model predictions, the stimu-
latory effect of estradiol on transcriptional activation of all
four genes was more prominent in MCF-7, LCC9 and
LCC1 cells, than in LCC2 cells, which contained the high-
est amount of ER. Treatment of the cells with a combin-
ation of estradiol and tamoxifen resulted in a certain level
of transcriptional inhibition as compared to estradiol
alone. The only exception was the expression of PGR in
LCC1 cells, where combining estrogen with tamoxifen led
to some additional stimulation of transcription.
Thus, the experimental results were in qualitative agree-
ment with the model predictions about non-monotonic de-
pendence of ER-induced gene expression on the amount of
ER. Indeed, the expression levels of each of the experimen-
tally studied genes in most cases, and under a variety of
treatment conditions, followed a trend of non-monotonous
dependence on the ER level, with the maximal expression
observed in either LCC9 or LCC1 cells, that are charac-
terised by medium levels of ER expression. Cells with the
highest amount of ER (LCC2) in most cases demonstrated
a lower level of transcriptional activation as compared to
LCC1 and LCC9.
Our model provides a consistent explanation for this
non-intuitive phenomenon, shedding light on the poten-
tial mechanism underlying the detected differences in
gene expression patterns between MCF-7, LCC9, LCC1
and LCC2 cell lines.
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monotonicity
We propose that the described phenomena of non-
monotonic transcriptional response to the increasing
concentration of ER fits well within the concept of "com-
binatorial inhibition" or "prozone effect" previously re-
ported for other multi-component systems [56-58]. In
summary, the concept suggests that certain types of multi-
meric protein complexes can be inhibited by high concen-
trations of one of its components. In 1997, Bray and Lay
[58] used modelling approach to analyse 30 different oli-
gomeric complexes and found that disproportionally high
concentration of one of the complex components may
cause suppression of multimeric complex assembly. This
is due to accumulation of smaller incomplete complexes
which sequester other proteins that are not present in
high concentrations and thereby prevent the formation of
fully functional complex. The effect was shown to be the
most pronounced for those proteins which serve as the
central core of the complex, forming multiple bonds with
other complex components. These ideas were supported by
a study of Levchenko et al. [57] who explored numerically
the role of a scaffold protein in a MAPK pathway, and
found that for any generic scaffold there exists a concentra-
tion value optimal for signal amplitude. These findings have
been further confirmed experimentally by Chapman et al.
[56], who studied the effect of over-expression of the scaf-
fold protein Ste5 on the MAPK pathway in yeast and
demonstrated that signal throughput exhibited a biphasic
dependence on scaffold concentration.
In the system of ER-related signalling, ER is at the core
of multimeric transcriptional complex, forming bonds
with several ligands, ERE and multiple transcriptional
co-regulators. Therefore, in line with predictions of [58]
and with our own findings (Figures 6 and 7) an excess of
ER is likely to cause a significant sequestration effect,
resulting in the abundance of incomplete transcription
complexes (like ER2D) and preventing from formation of
both fully and partly functional complexes (like ER2H2D,
ER2HD, ER2ID and ER2I2D).
Indeed, the analysis of the distribution of receptor-
ligand complexes (Figure 6E) and the composition of tran-
scription complexes present at ERE (Figure 6F) at various
levels of ER expression reveals that at high levels of ER
(e.g., as observed in LCC2), free ER2 dimers and ER2I
complexes become the prevailing forms of the receptor-
ligand complexes, whereas the relative amount of tran-
scriptionally more active complexes (especially ER2H and
ER2H2) significantly drops (Figure 6E). The excess of ER2
dimers as well as their higher affinity for ERE, as com-
pared with that of ER2I complex (see Table 1), allows them
to out-compete ER2I and other receptor-ligand complexes
for binding with target promoters. Consequently, slow
transcribing "incomplete" transcription complex (ER2D)become a prevailing type of complexes formed at ERE
(Figure 6F), that causes a general drop in transcription at
high expression level of ER, and may explain generally low
expression level of ER-dependent genes in LCC2 cells
(Figure 7A).
We suggest that the effect of such combinatorial in-
hibition may be an important factor in regulation of ER-
induced transcription, both in the absence and in the
presence of anti-estrogenic drugs.
Tamoxifen agonism is dependent on the parameters
associated with tamoxifen-receptor transcription
complexes
As suggested by GSA, the ER-dependent protein expres-
sion is highly sensitive to the variation of the parameters,
associated with the transcriptional activation induced by
tamoxifen-receptor complexes (ksr,i, K19). Exploration of
the steady state transcriptional response in the range of
ksr,i values (Figure 8A) revealed a potentially very strong
transcriptional stimulation in the range of high dose
tamoxifen at ksr,i > 0.03. Interestingly, the model predicts
that administration of the same concentration of tamoxi-
fen can lead to either up- or down-regulation of tran-
scription, depending on the value of ksr,i. For instance,
for ksr,i <0.02 high dose tamoxifen (>100 nM) would act
as a pure antagonist, effectively suppressing ER-induced
protein expression. However, in the range of ksr,i >0.03
the same dose of the drug would result in significant
transcriptional stimulation (area marked by yellow and
red). Thus, even a slight variation in ksr,i (e.g. caused by
a change in intracellular microenvironment) may cause a
significant change in transcriptional outcome, including
a steep transition from clearly antagonistic action of
tamoxifen to strong activatory effect.
Multiple recent studies have confirmed the crucial role
of intra-cellular micro-environment in determining the
ER-dependent transcriptional response. In particular,
there is increasing evidence that the gene and cell-
specific action of both estradiol and SERMs significantly
depend on the presence of transcriptional co-activators
and co-repressors, which, when recruited to the target
promoter, are capable of promoting or hindering the ac-
tivation of transcriptional machinery. For example, tam-
oxifen can act as ER antagonist in breast cancer cells
[13], but, at the same time it can have a partial agonistic ef-
fect in endometrium, thus causing endometrial hyperplasia
and even cancer [5]. These differences in tamoxifen action
have been attributed to the different levels of transcriptional
co-regulators present in breast and endometrium cells.
Romano et al. [14] report that differential co-regulator re-
cruitment explains the opposite transcriptional effect
observed at a number of ER-regulated genes in re-
sponse to OH-tamoxifen in breast cancer (T47D) and
endometrial cancer (ECC1) cells. Moreover, they
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tamoxifen in T47D and ECC1 cells can be, in fact, be
inverted by over-expressing either co-activator SRC-1 or
co-repressor SMRT.
Our model does not explicitly account for interaction
of co-regulators with the transcription complex (partly
because of the uncertainty of the kinetic parameters
associated with these processes, that inevitably would
over-complicate the model). However, the differential re-
cruitment of co-regulators to the target promoters as
well as their higher/lower expression levels can be imi-
tated by assigning a higher or a lower value to corre-
sponding transcription rate constants (e.g., ksr,i).
For instance, higher expression levels of co-activator
SRC-1 found in endometrial cells [15] could be inter-
preted as a higher value of ksr,i in our model. According
to the graph in Figure 8A, this could result in high agon-
istic action of tamoxifen, given the dose of the drug is
sufficiently high (>100 nM).Transcriptional response to tamoxifen rises along with
the increase in the amount of ER- responsive genes
According to GSA predictions, the magnitude of tran-
scriptional response to tamoxifen is strongly positively
correlated with the number of ER-responsive genes (Dt)
(Figure 5). As seen from Figure 8B, in our model, the
gradual increase in Dt resulted in significant elevation in
the overall ER-induced protein expression in the wide
range of tamoxifen concentrations, with more prominent
effect observed in medium and low tamoxifen dose range
(<100 nM).
One possible interpretation of this result is that overall
ER-induced protein expression increases when more
EREs become available for efficient ER binding.
This is in line with recent findings of Ross-Innes
et al. [19] who studied ER-binding events in primary
frozen breast cancer samples and demonstrated the ac-
quisition of additional ER-binding regions in tumors
with poor prognosis, as compared to good outcome
samples. Such a modified ER binding profile in poor
prognosis tumours was associated with upregulated
expression of corresponding genes. Similar "reprogram-
ming" of ER binding was also found in tamoxifen-
resistant cancer cell line models. In terms of our model
the acquisition of additional ER-binding regions can be
interpreted as an efficient increase in Dt. The model
predicts (Figure 8B), that higher levels of Dt may be
associated with the lack of tamoxifen efficiency. Indeed,
at Dt>0.3 nM even high concentrations of tamoxifen
(It> 1 μM) cause no more than 30% inhibition of ER-
induced transcription. Moreover, in the dose range of
10–100 nM the drug may cause some additional tran-
scriptional stimulation.Conclusions
The aim of this study was to develop a minimal mechan-
istic model of ER-dependent gene expression, which
could be applied for the analysis of transcriptional re-
sponse to natural hormone 17β-estradiol and SERMs in
the broad range of their concentrations.
The developed model represents a system of algebraic
equations, describing equilibrium binding of ER with
ligands and DNA, linked to a simple ODE model of ER-
induced gene expression. The model allows for the analysis
of the effects of two types of ER ligands: natural hormone
17β-estradiol, and its external competitor tamoxifen. It
should be noted that the model could be easily extended/
modified to include other ligands or combination of those,
including environmental phytoestrogens, if an appropriate
data set for evaluation of relevant binding parameters
becomes available.
The model was parameterised on several independent
data sets, measured both in vitro and in vivo cell culture
systems. Despite the broad diversity of experimental data
used for calibration of its separate blocks, the resulting
model was capable of satisfactorily describing the tam-
oxifen dose-dependence patterns of a reporter gene ex-
pression in HEK 293/hERα cell line, and provided a
plausible explanation of the mechanisms underlying ag-
onistic action of tamoxifen in the given cell line.
Apparently, many of the model parameters, including
the total amounts of individual species and some of the
binding parameters, are subject to biological variability
and likely to be cell-type specific. Therefore, with a view
to extending model conclusions to other cell types, we
sought to explore the behaviour of the key model read-
out (steady state protein expression level, p̄) in the wider
range of plausible parameter values, including those
found in cancer cells. We used global sensitivity analysis
to identify key control parameters, which are likely to
have the biggest impact on the ER-dependent transcrip-
tional response to tamoxifen. According to the GSA
results, the most influential parameters were: the total
amount of ER-responsive genes (Dt), expression level of
ER (ERt), background hormone concentration (Ht) and
parameters, associated with ER-tamoxifen transcription
complex (ksr,i). Continuation of the steady state model
solution within biologically plausible ranges of these
control parameters revealed a number of interesting
regulatory phenomena.
First of all, the transcriptional response to tamoxifen
demonstrated explicit non-monotonous dependence on
both tamoxifen dose and ER expression level, with dis-
tinct areas of high agonism within certain ranges of drug
and ER concentrations (Figure 6). Model-based analysis
of the composition of transcriptional response in the
area of high agonism revealed that in the range of low
and medium concentrations of tamoxifen, and at
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may act synergistically, resulting in a significant eleva-
tion of ER-dependent transcription.
Importantly, the prominence of this effect was directly
dependent on the background concentration of 17β-estra-
diol. At high dose tamoxifen the transcriptional response
was found to be extremely sensitive to the parameters of
transcription, induced by transcription complexes formed
by ER bound with tamoxifen, that is in line with recent
studies highlighting the important role of selective recruit-
ment of transcriptional co-regulators by ER-tamoxifen
complexes in defining agonistic action of tamoxifen [14,15].
Our findings suggest that transcriptional response to
tamoxifen is a complex non-linear function of many vari-
ables, with the key control role belonging to ER expression
level, hormone concentration, number of ER-responsive
genes and the capacity of ER-tamoxifen complexes to
stimulate transcription (e.g., by recruiting various co-
regulators of transcription).
The majority of existing studies into the effects of SERMs
and into associated risks of endometrial cancer have fo-
cused on the analysis of the impact of single individual fac-
tors on ER-dependent transcriptional activation and clinical
outcome. For instance, association of higher estradiol con-
centration in serum with a higher risk of endometrial can-
cer has been reported [59]. There is also growing evidence
of the important role of the specific changes in ER binding
profile and transcriptional co-regulator recruitment in the
emergence of tamoxifen resistance [7,19]. Other studies
highlighted the role of ERα expression level in regulating
ER-induced transcriptional response [54,60]. Our experi-
ments presented in the current study provided evidence for
non-linear dependence of ER-related transcriptional re-
sponse on the level of ERα expression.
Our theoretical analysis suggests that the effect of each
of these important factors on transcriptional outcome
should not be considered in isolation, since it can be
enhanced or attenuated by other key players implicated
in controlling ER-mediated transcriptional response,
whose role should not be overlooked.
At present, the only molecular biomarker routinely used
in clinical practice for stratifying patients for therapy with
tamoxifen is the presence of ERα expression in tumor cells.
Any positive level of ERα expression is considered sufficient
to justify the use of endocrine adjuvant therapy in almost
all patients [61]. The lack of efficacy of tamoxifen therapy
in significant group of patients as well as frequent emer-
gence of drug resistance question the practical utility of sin-
gle biomarker approach, and drive the research towards
looking for more sophisticated tests, e.g., by including pro-
filing for aberrations in additional genes, e.g., HER2, c-Myc,
cyclin D [62-64]. Our analysis also suggests that more com-
plex, or combinatorial, biomarkers are required. These
could include more accurate quantitative assessment ofindividual ER expression level and concentration of estra-
diol, as well as profiling for key transcriptional co-
regulators.
It must be emphasized, that our developed model is only
a crude approximation of highly complicated ensemble of
processes, associated with ER-mediated activation of tran-
scriptional machinery. In current model implementation
we have not explicitly included binding of ER with its tran-
scriptional co-regulators (such as AIB1, SRC1, NCoR and
SMART) and only indirectly accounted for activatory/in-
hibitory action of these molecules via variation of relevant
rate constants of transcription. Because of these simplifica-
tions our theoretical conclusions, drawn from the model
analysis, remain mainly of qualitative nature, and serve the
purpose of attracting attention to potential non-linear
effects in the system of ER-induced transcription and laying
the basis for their further investigation. Ideally, for more re-
liable approximation of the effects of SERMs in cancer cell
lines as well as for predicting potential outcome of tamoxi-
fen therapy in patients, further model refinement and more
systematic experimental studies are required, which would
allow more accurate mapping of the "high agonism" area in
the multi-dimensional space of the key biological para-
meters, controlling ER-dependent gene expression.
Methods
Equilibrium Model of ER dimerisation, binding with
ligands and ERE DNA
For the processes 1–20, depicted in Figure 1A and 1B,
the dissociation constants are defined as follows:
K 1 ¼ ER
2
ER2
;K2 ¼ ER2⋅HER2H ;K3 ¼
ER2H⋅H
ER2H2
;K4 ¼ ER⋅HERH ;
K5 ¼ ER⋅ERHER2H ;K6 ¼
ERH2
ER2H2
; K7 ¼ ER2⋅IER2I ; K8 ¼
ER2I⋅I
ER2I2
;
K 9 ¼ ER⋅IERI ; K10 ¼
ER⋅ERI
ER2I
; K11 ¼ ERI
2
ER2I2
;
K12 ¼ ERI⋅ERHER2HI ; K13 ¼
ER2I⋅H
ER2HI
; K14 ¼ ER2H⋅IER2HI
K15 ¼ ER2⋅DER2D ; K16 ¼
ER2H⋅D
ER2HD
; K17 ¼ ER2H2⋅DER2H2D ;
K 18 ¼ ER2I⋅DER2ID K19 ¼
ER2I2⋅D
ER2I2D
; K20 ¼ ER2HI⋅DER2HID ;
Under equilibrium conditions the following detailed
balances exist in the system:
K1K2 ¼ K4K5
K1K2K3 ¼ K 24K6
K1K7 ¼ K9K10
ER2 I D
Lebedeva et al. BMC Systems Biology 2012, 6:138 Page 17 of 22
http://www.biomedcentral.com/1752-0509/6/138K1K7K8 ¼ K 29K11
K2K14 ¼ K7K13
K9K12 ¼ K5K14
This means that six out of 14 Kds depicted in Figure
1A depend on others and can be expressed as follows:
K5 ¼ K1K2K4 ;K6 ¼
K1K2K3
K24
;K10 ¼ K1K7K9 ;K11 ¼
K1K7K8
K29
;
K12 ¼ K1K7K13K4K9 ;K14 ¼
K7K13
K2
:
Thus, under equilibrium conditions, the distribution
of species in the system is defined by the following sys-
tem of algebraic equations:
For ER binding with the hormone:
ER2 ¼ ER
2
K1
ð1Þ
ER2H ¼ ER
2
K1
H
K2
ð2Þ
ER2H2 ¼ ER
2
K1
H2
K2K3
ð3Þ
ERH ¼ ER⋅H
K4
ð4Þ
For ER binding with the inhibitor:
ER2I ¼ ER
2
K1
I
K7
ð5Þ
ER2I2 ¼ ER
2
K1
I2
K7K8
ð6Þ
ERI ¼ ER⋅I
K9
ð7Þ
ER2HI ¼ ER
2
K1
I⋅H
K7K13
ð8Þ
For binding of ER dimer complexes with ERE DNA
(D):
ER2D ¼ ER
2
K1
D
K15
ð9Þ
ER2HD ¼ ER
2
K1
H
K2
D
K16
ð10Þ
ER2H2D ¼ ER
2
K1
H2
K2K3
D
K17
ð11ÞER2ID ¼ K1 K7 K18 ð12Þ
ER2I2D ¼ ER
2
K1
I2
K7K8
D
K19
ð13Þ
ER2HID ¼ ER
2
K1
I⋅H
K7K13
D
K20
ð14Þ
For simplicity we assume that in the system shown in
Figure 1 the total concentrations of estrogen receptor
(ERt), hormone (Ht), inhibitor (It) and DNA (Dt) are
conserved. This assumption is justified for the model de-
scribing the data obtained in in vitro studies on purified
receptor and ERE, where the total concentration of each
of the species is unambiguously defined by the experi-
mental protocol. The mass conservation approximation
also holds for in vivo cellular systems, assuming that cel-
lular amounts of ER and DNA are maintained at some
quasi-steady state level, resulting from the balance bet-
ween the processes of their synthesis and degradation,
whereas hormone and drug concentrations are con-
trolled experimentally.
This allows definition of the concentrations of free
forms of these species as follows:
ER ¼ ERt  ERH  ERI  2⋅ðER2 þ ER2H
þER2H2 þ ER2I þ ER2I2 þ ER2HI þ ER2D
þER2HDþ ER2H2Dþ ER2IDþ ER2I2D
þER2HIDÞ
ð15Þ
H ¼ Ht  ERH  ER2H  ER2HI  ER2HID ER2HD
2⋅ ER2H2 þ ER2H2Dð Þ
ð16Þ
I ¼ It  ERI  ER2I  ER2HI  ER2HID
 ER2ID 2⋅ ER2I2 þ ER2I2Dð Þ ð17Þ
D ¼ Dt  ER2D ER2HD ER2HID ER2ID
 ER2H2D ER2I2D ð18ÞSimplified model of ER -dependent transcription/
translation
To describe the ER-dependent expression of an estrogen-
responsive gene, we linked the algebraic system (1–18) to
a simplified kinetic model of transcription and translation
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radation of corresponding mRNA (r) and protein (p):
dr
dt
¼ ksr ER2HDþ ER2H2Dð Þ þ ksr;i ER2IDþ ER2I2Dð Þþ
þksr;hiER2HIDþ ksr;bER2D kdrr;
ð19Þ
dp
dt
¼ kspr  kdpp ð20Þ
Here we assume that the rate of mRNA synthesis is
proportional to the concentration of transcription com-
plexes assembled at ERE, and that different forms of
ER2-ligand complexes differ by their capability to induce
transcription. In particular, we assume that unliganded
ER dimer can stimulate transcription at some basal level
with the rate constant ksr,b; complexes ER2H and ER2H2
have an equal potency to induce transcription (ksr); simi-
larly, ER2I and ER2I2 stimulate transcription with the
rate constant ksr,i, whereas the heterodimer ER2HI has a
different capacity to induce transcription (ksr,hi). Those
assumptions were based on current understanding of
the potency of various forms of ER to induce transcrip-
tion. For example, Fowler et al. [24,25] demonstrated
that increased ERα expression in MCF7 cells resulted in
activation of ER-responsive gene even in the absence of
estrogen, that proves the ability of unliganded ER dimers
to bind to ERE and stimulate transcription. The ability
of tamoxifen to induce transcription has been confirmed
in multiple studies on agonist/antagonist effects of
SERMs [11,38,41,42,65].
It is easy to demonstrate that in the system (19–20)
the steady state concentrations of RNA (rˉ ) and protein
(pˉ ) are fully defined by the concentrations of active tran-
scription complexes as follows:
r ¼ vtr
kdr
; ð21Þ
p ¼ vtr
κ
; ð22Þ
where
vtr ¼ ksr ER2HDþ ER2H2Dð Þ
þ ksr;i ER2IDþ ER2I2Dð Þ þ ksr;hiER2HID
þ ksr;bER2D; ð23Þ
κ ¼ kdpkdr
ksp
ð24Þ
Here vtr describes the overall rate of ER-dependent
transcription, stimulated by various types of transcrip-
tion complexes; κ is the ratio of the rate constants of
protein degradation, mRNA degradation and protein
synthesis.Thus, our simplified model of ER-dependent gene ex-
pression represents a system of algebro-differential equa-
tions (1–20). The steady state solution of the system can
be found by solving the system of algebraic equations
(1–18, 21–24). Importantly, using an equilibrium and
steady state approximation allowed us to reduce the num-
ber of independent model parameters from 45 to 23.
Global sensitivity analysis (GSA)
GSA of the model of ER-dependent gene expression was
performed according to the following algorithm:
Step1: Definition of the set of parameters to perturb and
setting their boundaries
We perturbed all independent kinetic parameters of the
model (dissociation and reaction rate constants) and
total concentrations of model species, with the exception
of the inhibitor concentration (It), whose value was fixed
to a certain value during each run of GSA. In total we
performed 138 GSA runs for 138 different concentra-
tions of tamoxifen to evenly cover the drug dose range
of 0.01-3000 nM on a logarithmic scale. The full list of
parameters used for GSA and their constraints can be
found in Additional File 6.
Step 2: Sampling N random parameter sets from the
parameter space
To randomly sample the parameter sets from the hyper-
cube defined by parameter ranges we used Latin Hyper-
cube Sampling (LHS) algorithm [66]. LHS represents a
variant of stratified sampling based on simultaneous
variation of all input parameters, that ensures that indi-
vidual parameter ranges are evenly covered, and each
parameter combination is unique. For our analysis we
sampled 50000 random parameter sets.
Step 3: Simulating the model for each parameter set
For each randomly selected parameter set we ran a
simulation of the model and calculated the steady state
level of protein expression pˉ as defined in equations
(22–24).
Step 4. Calculating sensitivity indices
To analyse the sensitivity of the steady state protein ex-
pression pˉ to the variation of model parameters we used
a variant of Partial Rank Correlation Coefficient (PRCC)
analysis, as one of the most efficient and reliable
sampling-based techniques [67]. For each fixed dose of
tamoxifen, for each model parameter Kj, we calculated
the PRCC index, that represents a standardized sensitiv-
ity metric of correlation between the value of the model
readout (pˉ ) and model parameter Kj .To reduce the in-
fluence of nonlinearity, the correlation was calculated
based upon ranks rather than absolute values.
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ation coefficient rj between the two residuals kj = Kj
R −
Kj
L and p = pR − pL, where Kj
R and pR are rank trans-
formed Kj and pˉ ; Kj
L and pL are the linear regression
models defined as follows [67]:
KLj ¼ a0 þ
Xn
l ¼ 1
l≠j
alK
R
l;
pL ¼ b0 þ
Xn
l ¼ 1
l≠j
blK
R
l
Thus XN   
rj ¼ i¼1
kij  μk pi  μpﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃXN
i¼1
kij  μk
 2XN
i¼1
pi  μp
 2s ;
where N is the number of parameter sets sampled from
the model parameter space; μk and μp are respective
sample means.
Importantly, the sign of a PRCC indicates how the
variation of each parameter affects the value of pˉ : the
positive index corresponds to the parameter whose
higher value is likely to be associated with a higher tran-
scriptional response, and vice versa. The value of PRCC
indices are distributed between - 1 and 1 with 0 indicat-
ing those parameters to whose variation the model out-
put is completely insensitive.
Computation
Model construction and simulation was performed with
the use of the DBSolve package [68]. Fitting the model
to experimental data involved minimisation of least
square deviation between experimental and theoretical
curves, with the use of Hooke and Jeeves algorithm as
implemented in DBsolve package. Global sensitivity ana-
lysis made use of KINSOL solver of SUNDIALS [69].
Experimental methods
Cell culture
MCF-7 cells were routinely grown in phenol red con-
taining Dulbecco’s Modified Eagle medium (DMEM)
supplemented with 10% fetal calf serum (FCS), Penicil-
lin (100 Units/ml) and Streptomycin (100 mg/ml).
LCC1, LCC2 and LCC9 cells (source: Dr.Robert Clarke,
V.T.Lombardi Cancer Research Center, Georgetown
University Medical School, Washington, D.C., USA)
were routinely kept in phenol red free containing
Dulbecco’s Modified Eagle medium (DMEM) supple-
mented with 5% dextran activated charcoal stripped
fetal calf serum (DCC), Penicillin (100 Units/ml)
Streptomycin (100 mg/ml) and 2mM Glutamine [70-72] All cells were grown at 37°C in 5% CO2. To deter-
mine the effects of 17β-estradiol (E2) and tamoxifen on
mRNA expression, MCF-7 cells were seeded in 6 well
plates in phenol red containing DMEM with 10%FBS
for 24 h. The media was changed to phenol-red-free
DMEM with 5% DCC for 48 h. The cells were then sup-
plemented with media containing either 1 nM E2, 1 μM
tamoxifen or both. LCC1, LCC2 and LCC9 cells were
seeded in 6 well plates in phenol-red-free containing
DMEM with 5%DCC and after 24h supplemented with
E2 and/or tamoxifen.RNA extraction and RT-PCR
Extraction of total RNA from whole cells was per-
formed using Tri-Reagent (Sigma, Poole, Dorset) as per
manufacturer instructions. RNA concentration was
measured using a spectrophotometer. QuantiTect™-
SYBRWGreen system (Quiagen cat#204243) was used
according to the manufacturers instructions for one
step RT-PCR in a total of 15μl reaction volumes includ-
ing 0.5 μM each primer and 40ng RNA. Real Time
cycler conditions were RT: 50°C for 30 min; PCR: initial
activation 95°C for 15 min; followed by 40 cycles of de-
naturation 94°C for 15 sec, annealing 57°C for 30 sec,
extension 72°C for 30 sec; and a final extension of 72°C
for 60 sec. The following primers were used:
TFF1: TTGTGGTTTTCCTGGTGTCA and
CCGAGCTCTGGGACTAATCA
PGR: GTCAGTGGGCAGATGCTGTA and
AGCCCTTCCAAAGGAATT
CTSD: CCCGAGGTGCTCAAGAACTA and
TCACGTAGGTGCTGGACTTG
MYC: TTCGGGTAGTGGAAAACCAG and
AGCAGCTCGAATTTCTTCCA
ACTIN: CTACGTCGCCCTGGACTTCGAGC and
GATGGAGCCGCCGATCCACACGG
cDNA was analyzed using a Rotorgene 2000 (Corbett
Research, Cambridge, UK).Additional files
Additional file 1: Full ODE model of ER-induced gene expression.
Additional file 2: Parameterisation of the separate blocks of the
model.
Additional file 3: Figure S1. The full spectrum of sensitivity of ER-
dependent protein expression to the variation of the model parameters,
calculated in the broad range of tamoxifen concentrations.
Additional file 4: Estimation of biologically plausible parameter
constraints.
Additional file 5: An animation, demonstrating how the 3D graph
shown in Figure 6C evolves with gradual increase in background
estradiol concentration.
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